Could stem cells offer a lifeline for sudden liver failure?

NCT ID NCT06740149

Completed Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates whether infusions of bone marrow stem cells (CG-BM1) can safely help people with acute-on-chronic liver failure, a life-threatening condition where the liver suddenly stops working. The trial involves 90 adults and will test different doses of stem cells given intravenously. Researchers are checking for side effects and whether the treatment can improve survival without needing a liver transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bone marrow mesenchymal stem cells (CG-BM1)
What this could lead to: If successful, this could offer a new treatment to help people with acute-on-chronic liver failure survive longer without needing a liver transplant.
What could go wrong: This is an early-phase trial, so the stem cell therapy may not work as hoped, and there could be side effects like allergic reactions or infections. The results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE-ON-CHRONIC LIVER FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acute-On-Chronic Liver Failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE-ON-CHRONIC LIVER FAILURE

Contacts and locations

Locations

Third Affliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, 510630, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.